Boston, MA -- (ReleaseWire) -- 06/06/2014 -- BMI View: While economic growth is boosting demand for pharmaceuticals in Bangladesh, income inequality continues to drive the purchase of counterfeit medicines. In November 2013, the government vowed to continue fighting the growing industry of substandard, counterfeit and life-endangering medicines - a positive development for patients. C ounterfeiting hijacks brand s and infringes legitimate pharmaceutical manufacturers ' patent and trademark rights - affecting their revenue - earning abilities in the Bangladeshi pharmaceutical market.
Headline Expenditure Projections
- Pharmaceuticals: BDT124.25bn (US$1.52bn) in 2012 to BDT138.80bn (US$1.76bn) in 2013; +11.7% in local currency terms and +16.1% in US dollar terms.
- Healthcare: BDT349.08bn (US$4.27bn) in 2012 to BDT399.56bn (US$5.07bn) in 2013; +14.5% in local currency terms and +18.9% in US dollar terms.
View Full Report Details and Table of Contents
Risk/Reward Ratings: While geographic diversification and investment into the pharmaceutical and healthcare sectors of emerging economies such as Bangladesh may be a favourable strategy for any multinational pharmaceutical company, it is vital that a company recognises both the rewards and the risks present in a market. For Q114, Bangladesh stands at 16th position out of the 18 regional markets surveyed. Its overall rating of 40 out of 100 remains considerably lower than the average for the region.
Key Trends And Developments
In October 2013, it was reported that the number of heart disease patients and spending on treatment have been rising sharply in Bangladesh. For example, data from the National Heart Foundation Hospital and Research Institute (NHFHRI) in Dhaka suggest that a total 18,610 patients were admitted in 2012, a growth of 13% year-on-year from 16,471 patients admitted in 2011.
Bangladesh's Dhaka Medical College and Hospital opened its new 10-storey, 600-bed second building in October 2013. Another Bangladeshi medical college, the Faridpur Medical College and Hospital, opened its new...
The Bangladesh Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladeshi pharmaceutical and healthcare industry.
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Bangladesh to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Turkey Pharmaceuticals & Healthcare Report Q3 2014
- Slovenia Pharmaceuticals & Healthcare Report Q3 2014
- Lebanon Pharmaceuticals & Healthcare Report Q3 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q3 2014
- Taiwan Pharmaceuticals & Healthcare Report Q3 2014
- Colombia Pharmaceuticals & Healthcare Report Q3 2014
- Singapore Pharmaceuticals & Healthcare Report Q3 2014
- Puerto Rico Pharmaceuticals & Healthcare Report Q3 2014
- Hong Kong Pharmaceuticals & Healthcare Report Q3 2014
- Germany Pharmaceuticals & Healthcare Report Q3 2014